![Sheraz Mian Sheraz Mian](https://staticx.zacks.com/images/mugshots/sheraz_mian/sheraz_mian-4.png)
Top Research Reports for Microsoft, Biogen & Home Depot
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tuesday, January 17 2017
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Biogen (BIIB) and Home Depot (HD).
Buy rated Microsoft shares lagged the Zacks Tech sector through the fall, but have led the way over the last three months (up +8.7% versus +3.3%) on greater appreciation for the company's reorganization and repositioning. Notably, estimates have been going up ahead of the company's Q2 earnings release. The Zacks analyst points to the company's continuing enterprise strength, benefits from the Office 365 subscription model, strong growth prospects of Azure and promising new products. The recent acquisition of artificial intelligence startup Maluuba is a big positive for the company given the growing demand for artificial intelligence techniques throughout the world. Further, the anticipated completion of the LinkedIn acquisition will boost Microsoft's presence in the social media market. (You can read the full research report on Microsoft here >>)
Biogen shares initially gained from the post-election rally, but have since underperformed the broader pharma space as the macro issues plaguing the space still continue. These issues notwithstanding, the analyst likes the Buy rated stock’s strong position in the multiple sclerosis market primarily due to a wide range of products. Cost cutting efforts and MS franchise sales should continue to drive growth. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise. Estimates have also gone up lately ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters. (You can read the full research report on Biogen here>>)
Buy rated Home Depot shares have outperformed the Zacks Retail sector over the last three months, gaining +7.4% over the period versus the sector’s +0.8% gain in the year-to-date period. Solid execution and a consistent housing market recovery have been its primary growth drivers. The analyst likes Home Depot’s focus on developing merchandising tools, which, along with investment in building its interconnected capabilities is expected to boost its top line, and enhance market share. The company is on track to achieve its long-term dividend payout, share repurchase and return on investment targets. Estimates have been stable ahead of the company’s Q4 earnings release, while it has positive record of earnings surprises in recent quarters. (You can read the full research report on Home Depot here >>)
Other noteworthy reports we are featuring today include 21st Century Fox (FOXA), Bristol-Myers (BMY) and Berkshire Hathaway (BRK.B).
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Sheraz Mian
Director of Research
Note: Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview.
If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on BIIB - FREE
Get the latest research report on MSFT - FREE
Get the latest research report on BMY - FREE
Get the latest research report on HD - FREE
Get the latest research report on BRK.B - FREE
Get the latest research report on FOXA - FREE